Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10039136HBVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS30073496HIVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS30073497HIVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20011278HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029983HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029984HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029985HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029986HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029987HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20064469HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TCGA Plot Options
Drug Information
GeneHTR2C
DrugBank IDDB06446
Drug NameDotarizine
Target IDBE0000533
UniProt IDP28335
Regulation Type
PubMed IDs9379783
CitationsFarre M, Roset PN, Llorente M, Marquez M, Albet C, Perez JA, Herrero E, Ortiz JA: Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration. Methods Find Exp Clin Pharmacol. 1997 Jun;19(5):343-50.
GroupsInvestigational
Direct ClassificationDiphenylmethanes
SMILESC(CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1)CC1(OCCO1)C1=CC=CC=C1
Pathways
PharmGKB
ChEMBLCHEMBL2106316